The estimated Net Worth of Brian T Carley is at least $7.43 Millón dollars as of 30 June 2024. Mr. Carley owns over 78 units of Medpace Inc stock worth over $7,277,567 and over the last 8 years he sold MEDP stock worth over $0. In addition, he makes $149,994 as Independent Director at Medpace Inc.
Brian has made over 8 trades of the Medpace Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently he exercised 78 units of MEDP stock worth $26,096 on 30 June 2024.
The largest trade he's ever made was exercising 13,782 units of Medpace Inc stock on 20 February 2024 worth over $364,396. On average, Brian trades about 1,145 units every 24 days since 2016. As of 30 June 2024 he still owns at least 21,752 units of Medpace Inc stock.
You can see the complete history of Mr. Carley stock trades at the bottom of the page.
Brian T. Carley serves as Independent Director of the Company. He has served as a member of our Board since July 1, 2016. Mr. Carley is currently the Senior Vice President and Chief Financial Officer of Clubessential Holdings, LLC, a privately held Software as a Service (SaaS) holding company providing member engagement, club management and athletics software. He previously served as President and Chief Executive Officer of the Cincinnati USA Regional Chamber from 2014 to 2015. From 2002 to 2014, Mr. Carley worked at Deloitte & Touche LLP, where he served as regional and office audit division head and audit partner. Before joining Deloitte & Touche LLP, Mr. Carley was employed by Arthur Andersen LLP from 1976 to 2002. There, he served as office managing partner and audit partner. Mr. Carley also has extensive experience serving as a director for a diverse group of companies, including as a director of Assurex Health, Inc. from 2015 until its sale in August 2016, and as a director and officer of numerous civic and charitable organizations. Mr. Carley currently sits on the board of directors of the following private companies or civic and charitable organizations: Clubessential, LLC, ClubReady, LLC, PrestoSports, LLC, Vermont Systems, Inc., TriHealth, Inc. and Cincinnati Works. Mr. Carley received his Bachelor of Science in Accountancy from the University of Illinois, and he is a retired Certified Public Accountant. Mr. Carley was chosen as a director because of his significant financial, accounting and directorship experience from his background as an audit partner at Deloitte & Touche LLP and Arthur Andersen LLP and his experience serving on boards.
As the Independent Director of Medpace Inc, the total compensation of Brian Carley at Medpace Inc is $149,994. There are 8 executives at Medpace Inc getting paid more, with August Troendle having the highest compensation of $7,712,840.
Brian Carley is 66, he's been the Independent Director of Medpace Inc since 2016. There are 1 older and 13 younger executives at Medpace Inc. The oldest executive at Medpace Holdings Inc is Fred Davenport, 68, who is the Lead Independent Director.
Brian's mailing address filed with the SEC is C/O MEDPACE HOLDINGS, INC., 5375 MEDPACE WAY, CINCINNATI, OH, 45227.
Over the last 8 years, insiders at Medpace Inc have traded over $3,140,136,825 worth of Medpace Inc stock and bought 2,899,276 units worth $330,034,155 . The most active insiders traders include Limited Partnership Medpace..., August J. Troendle y Investors, Llc Medpace. On average, Medpace Inc executives and independent directors trade stock every 9 days with the average trade being worth of $40,224,347. The most recent stock trade was executed by Robert O. Kraft on 22 August 2024, trading 8,127 units of MEDP stock currently worth $346,373.
a therapeutically focused leader in research-based drug development, medpace builds strong strategic partnerships with select sponsors to advance the most efficient and cost-effective path to drug approval. as a full service, global clinical research organization (cro), medpace sees itself as a steward of your drug, leveraging its extensive medical and regulatory expertise to deliver additional input, strategy, and efficiencies to each and every phase of the clinical trial. from custom solutions addressing the needs of small and midsize biotechnology companies to full-service offerings for global pharmaceutical companies, medpace has the breadth, depth, and flexibility to deliver a superior result, specific to your needs, on six continents.
Medpace Inc executives and other stock owners filed with the SEC include: